Why Axsome Therapeutics Stock Is Soaring Today

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.3% on the day.

A senior analyst at the Japanese banking giant Mizuho raised his price target significantly for Axsome on Monday in a note to investors after news broke that Axsome had settled an important piece of litigation.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

No generic competition for now

Axsome announced Monday that it had settled its suit with fellow drugmaker Teva Pharmaceuticals. Axsome was accusing Teva of patent infringement after the latter sought FDA approval to market a generic version of Axsome's key drug, Auvelity. The settlement protects Axsome's exclusive rights over Auvelity for roughly 14 years -- a big win for Axsome.

Mizuho has confidence in Axsome

The resolution led Mizuho's Graig Suvannavejh, PhD, to raise his price target for Axsome from $137 to $195 a share, maintaining his outperform rating. Suvannavejh, who joined Mizuho from Goldman Sachs, explained that the news removes uncertainty around Axsome's bottom line. The clarity makes Axsome more attractive to potential strategic partners -- other drug companies that can help elevate Auvelity sales. He also cited positive momentum from the company's development pipeline. Axsome expects results from two phase 3 trials within the quarter.

Suvannavejh is not alone. Axsome has received positively revised price targets following the settlement from analysts across Wall Street.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $346,349!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,160!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $554,176!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 3, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics and Goldman Sachs Group. The Motley Fool has a disclosure policy.